AT-101 | Phase | Patients | Patients | Combined | Disease | Adverse Effects | ORR | Stab. | Ref |
---|---|---|---|---|---|---|---|---|---|
NCT00891072 | I | 24 | Pre-treated | CARB/PAC | AST | ADP/Neut/Throm | 4.16% CR; 16.66% PR | 33% | [401] |
NCT00540722 | II | 56 | Untreated (3 wks) | -single- | GCG | GI/FAT | – | – | – |
NCT00848016 | II | 29 | – | -single- | ADC | Anem/Naus/FAT | – | – | – |
NCT00544596 | I | 27 | Untreated (4 wks) | CIS/ETOP | ST/SCLC | – | – | – | – |
NCT00773955 | II | 14 | Pre-treated | -single- | SCLC | Anem/GI | 0% CR; 0% PR | – | – |
NCT00666666 | II | 55 | Untreated (4 wks) | LHRH/BIC | MPC | Anem/GI/AT | 18–60% Decreased PSA | – | – |